Patrick Ogle Takes 15.9% Stake in cbdMD, Gains Board Nomination Right
Patrick Ogle, via Akretive Holdings, acquired 2.23 million shares of cbdMD (15.9% stake) on October 30, 2026. The asset purchase agreement grants Akretive the right to nominate a director for cbdMD's committee, but not a guaranteed board seat. Akretive also holds a senior secured promissory note.
How this was made

The 30-second read
Why it matters
The 13D filing introduces a new major shareholder with board nomination rights, which may affect corporate governance and future strategic direction.
Market read
The filing is a primary disclosure for a micro‑cap, likely prompting short‑term price movement and increased analyst coverage.
What to watch
Potential future dilution if the investor seeks additional capital or a merger.
Background
cbdMD, Inc. is a publicly traded cannabis‑derived pharmaceutical company listed on the OTC market under the ticker YCBD.
Ticker impact
Patrick Ogle, via Akretive Holdings, acquired a 15.9% stake in cbdMD, Inc. by purchasing 2,229,805 shares under a newly filed Schedule 13D.
likely upward pressure as the market prices in the large stake and potential board influence
A 13D filing revealing a near‑20% stake is material for a micro‑cap; such ownership changes often lead to short‑term buying interest.
Market effects
May draw attention to the cannabis sector and could influence peer valuations.
Primarily U.S. OTC market; limited broader regional effect.
Low global relevance beyond niche cannabis investors.
Counterpoint
The stake could be a strategic move to push for changes that may unsettle current management.
Key entities
- InvestorPatrick Ogle
Managing member of Akretive LLC, leading the acquisition of a 15.9% stake in cbdMD.
- Investment VehicleAkretive Holdings, LLC
Entity used by Ogle to purchase shares and a senior secured promissory note.


